353 related articles for article (PubMed ID: 24721105)
1. The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer.
Crippa S; Salgarello M; Laiti S; Partelli S; Castelli P; Spinelli AE; Tamburrino D; Zamboni G; Falconi M
Dig Liver Dis; 2014 Aug; 46(8):744-9. PubMed ID: 24721105
[TBL] [Abstract][Full Text] [Related]
2. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
3. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
[TBL] [Abstract][Full Text] [Related]
4. The role of 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the management of patients with carcinoma of unknown primary.
Deonarine P; Han S; Poon FW; de Wet C
Scott Med J; 2013 Aug; 58(3):154-62. PubMed ID: 23960054
[TBL] [Abstract][Full Text] [Related]
5. Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis?
Jaffe TA; Neville AM; Bashir MR; Uronis HE; Thacker JM
Colorectal Dis; 2013 Nov; 15(11):e654-8. PubMed ID: 23910050
[TBL] [Abstract][Full Text] [Related]
6. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer.
Yang Z; Pan L; Cheng J; Hu S; Xu J; Ye D; Zhang Y
Int J Urol; 2012 Jul; 19(7):639-44. PubMed ID: 22452420
[TBL] [Abstract][Full Text] [Related]
8. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
9. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study.
Hitier-Berthault M; Ansquer C; Branchereau J; Renaudin K; Bodere F; Bouchot O; Rigaud J
Int J Urol; 2013 Aug; 20(8):788-96. PubMed ID: 23279605
[TBL] [Abstract][Full Text] [Related]
10. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
11. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin.
Algin E; Ozet A; Gumusay O; Cetin B; Akdemir UO; Benekli M; Coskun U; Uner A; Kapucu O; Buyukberber S
Ann Nucl Med; 2014 Nov; 28(9):891-6. PubMed ID: 25270711
[TBL] [Abstract][Full Text] [Related]
12. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.
Ikenaga N; Nakata K; Hayashi M; Nakamura S; Abe T; Ideno N; Murakami M; Fujimori N; Fujita N; Isoda T; Baba S; Ishigami K; Oda Y; Nakamura M
J Gastrointest Surg; 2023 Feb; 27(2):337-346. PubMed ID: 36652179
[TBL] [Abstract][Full Text] [Related]
14. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.
Mertens LS; Fioole-Bruining A; van Rhijn BW; Kerst JM; Bergman AM; Vogel WV; Vegt E; Horenblas S
J Urol; 2013 May; 189(5):1687-91. PubMed ID: 23142689
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
Leblanc E; Gauthier H; Querleu D; Ferron G; Zerdoud S; Morice P; Uzan C; Lumbroso S; Lecuru F; Bats AS; Ghazzar N; Bannier M; Houvenaeghel G; Brenot-Rossi I; Narducci F
Ann Surg Oncol; 2011 Aug; 18(8):2302-9. PubMed ID: 21347790
[TBL] [Abstract][Full Text] [Related]
16. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
17. [Positron emission tomography/computed tomography for lung cancer staging].
Ladrón de Guevara H D; Furnaro L F; Yévenes A S; Clavero R JM; Lazo P D; Rodríguez D P; Piottante B A; Pefaur D R; Pardo B C
Rev Med Chil; 2015 Jan; 143(1):22-9. PubMed ID: 25860265
[TBL] [Abstract][Full Text] [Related]
18. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
Kim YI; Kim SK; Paeng JC; Lee HY
Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
[TBL] [Abstract][Full Text] [Related]
20. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
